PCI

PCI may refer to:

Business and economics

Organizations

Conventional PCI

Conventional PCI, often shortened to PCI, is a local computer bus for attaching hardware devices in a computer. PCI is the initialism for Peripheral Component Interconnect and is part of the PCI Local Bus standard. The PCI bus supports the functions found on a processor bus but in a standardized format that is independent of any particular processor's native bus. Devices connected to the PCI bus appear to a bus master to be connected directly to its own bus and are assigned addresses in the processor's address space. It is a parallel bus, synchronous to a single bus clock.

Attached devices can take either the form of an integrated circuit fitted onto the motherboard itself (called a planar device in the PCI specification) or an expansion card that fits into a slot. The PCI Local Bus was first implemented in IBM PC compatibles, where it displaced the combination of several slow ISA slots and one fast VESA Local Bus slot as the bus configuration. It has subsequently been adopted for other computer types. Typical PCI cards used in PCs include: network cards, sound cards, modems, extra ports such as USB or serial, TV tuner cards and disk controllers. PCI video cards replaced ISA and VESA cards until growing bandwidth requirements outgrew the capabilities of PCI. The preferred interface for video cards then became AGP, itself a superset of conventional PCI, before giving way to PCI Express.

Ibrutinib

Ibrutinib (USAN, also known as PCI-32765 and marketed under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase (BTK).

Ibrutinib developed by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma.

It was approved by the US Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia. In January 2015, ibrutinib was approved by the FDA for treatment of Waldenström's macroglobulinemia, a form of non-Hodgkin's lymphoma. According to the Wall Street Journal by January 2016 isbrutinib, a specialty drug, cost US$116,600 to $155,400 a year wholesale in the United States. In spite of discounts and medical insurance, the prohibitive price causes some patients to not fill their prescriptions. The company marketing the drug, AbbVie, did not develop the drug but acquired it through an acquisition in May 2015. AbbVie estimates global sales of the drug at US$1 billion in 2016 and $5 billion in 2020.